NDAINTRAVENOUSPOWDERPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZERBAXA is a fixed-dose intravenous combination of ceftolozane (a fifth-generation cephalosporin) and tazobactam (a beta-lactamase inhibitor) approved for treating complicated urinary tract infections and complicated intra-abdominal infections. It is designed to overcome resistance mechanisms in gram-negative bacteria, particularly Pseudomonas aeruginosa. The drug represents an advance in the treatment of multidrug-resistant bacterial infections.
$0.013BPart D
Peak9.3 years to LOEProduct is at peak lifecycle stage with modest Part D spend (~$13M in 2023), suggesting a stable specialty injectable portfolio requiring focused commercial and medical support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZERBAXA positions you in the specialty infectious disease market, a niche but strategically important segment driven by hospital formulary decisions and infection control teams. Career growth depends on deepening clinical knowledge, building healthcare provider relationships, and preparing for competitive and patent pressures over the next decade.
Brand Manager
Worked on ZERBAXA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.